Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study. The purpose of this study is to assess the long-term safety of UT-15C and to assess the effects of long-term treatment with UT-15C on exercise capacity.
Inclusion Criteria:
Exclusion Criteria:
Sacramento, California 95817, United States
Jacksonville, Florida 32209, United States
Philadelphia, Pennsylvania 19104, United States
Pittsburgh, Pennsylvania 15213, United States
CABA, Buenos Aires C1425DUH, Argentina
Belo Horizonte, Minas Gerais 30130-100, Brazil
Botucatu, São Paulo 18618-970, Brazil
São Paulo, São Paulo 05403-000, Brazil
Shanghai, Shanghai Municipality 200120, China
Lille, Hauts-de-France 59037, France
Marseille, Provence-Alpes-Côte d'Azur Region 13015, France
Bochum, North Rhine-Westphalia 44789, Germany
Hyderabad, Andhra Pradesh 500 001, India
Hyderabad, Andhra Pradesh 500 063, India
Mumbai, Maharashtra 400012, India
Petach Tikvah, Petah Tiqwa 49100, Israel
Krakow, 61848, Poland